Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Zhang on the State of Risk Stratification in mCRPC

August 30th 2021

Jingsong Zhang, MD, PhD, discusses the current state of risk stratification in metastatic castration-resistant prostate cancer.

External-Beam Radiation Plus Androgen Suppression Improves EFS, DFS Only in Intermediate-Risk Prostate Cancer

August 27th 2021

Six-months of adjuvant androgen suppression plus 74 Gy or 78 Gy of concurrent external-beam radiation led to a statistically significant improvement in event-free survival and disease-free survival but failed to improve distant metastasis-free survival and overall survival vs external-beam radiation alone in patients with intermediate-risk prostate cancer.

Dr. Abida on Future Research Directions in mCRPC

August 26th 2021

Wassim Abida, MD, PhD, discusses future research directions in the treatment of patients with metastatic castration-resistant prostate cancer.

Dr. Garg on the Emergence of Antiandrogen Agents in nmCRPC

August 25th 2021

Natasha Garg, DO, discusses the emergence of antiandrogen agents in the nonmetastatic castration-resistant prostate cancer treatment paradigm.

Dr. Burnham on Correlations Between Race and HER2 Positivity in Prostate Cancer

August 24th 2021

Leanne Burnham, PhD, discusses the correlation between HER2 positivity and race in patients with prostate cancer.

Dr. Agarwal on the Efficacy of Intensified ADT in mHSPC

August 24th 2021

Neeraj Agarwal, MD, discusses the efficacy of intensified androgen deprivation therapy in patients with newly diagnosed, metastatic, hormone-sensitive prostate cancer.

Dr. Slovin on Selecting Among Available Treatment Options in mCSPC

August 24th 2021

Susan F. Slovin, MD, PhD, discusses selecting among available treatment options for patients with metastatic castration-sensitive prostate cancer.

Dr. Shore on the Utility of PSMA PET Imaging Agent Piflufolastat F 18 for Prostate Cancer

August 23rd 2021

Neal D. Shore, MD, FACS, medical director of the Carolina Urologic Research Center, discusses the clinical utility of piflufolastat F 18 in identifying suspected metastasis or recurrence of prostate cancer.

Dr. Tagawa on the Integration of PSMA-Targeted Agents in Prostate Cancer

August 23rd 2021

Scott Tagawa, MD, MS, FACP, discuss the integration of targeted agents in prostate cancer.

Dr. Morris on Findings From the TheraP Study in mCRPC

August 19th 2021

Michael J. Morris, MD, discusses findings from the phase 2 TheraP study, and how they led to the development of the phase 3 VISION trial in metastatic castration-resistant prostate cancer.

Dr. Burgess on the Integration of PARP Inhibitors in Prostate Cancer

August 19th 2021

Earle Burgess, MD, discusses the integration of PARP inhibitors in advanced prostate cancer.

Novel Compound Looks to Shake Up mCRPC Treatment Landscape

August 19th 2021

The discovery of an agent with a unique mechanism of action led investigators to examine sabizabulin, an oral therapy that binds to the colchicine binding site on the microtubule to crosslink α and β tubulin and inhibits microtubule polymerization.

Dr. Abida on Data from the PROfound Study in mCRPC

August 19th 2021

Wassim Abida, MD, PhD, discusses data from the phase 3 , PROfound trial in patients with metastatic castration-resistant prostate cancer.

Dr. Morris on the Efficacy of 177Lu-PSMA-617 Plus Best SOC in mCRPC

August 19th 2021

Michael J. Morris, MD, discusses the efficacy of Lutetium 177 PSMA-617 as a treatment for patients with metastatic castration-resistant prostate cancer.

Dr. Abida on the Limitations of PARP Inhibitors in Prostate Cancer

August 16th 2021

Wassim Abida, MD, PhD, discusses the limitations of PARP inhibitors in prostate cancer.

Tissue and Liquid Biopsies in Advanced Prostate Cancer

August 16th 2021

Dr Scott T. Tagawa comments on the pros and cons of liquid and tissue biopsies used to assess patients with advanced prostate cancer.

Precision Medicine in Advanced Prostate Cancer

August 16th 2021

A panel of physicians who work in the field of genitourinary oncology comment on the evolving role of precision medicine in advanced prostate cancer.

Dr. Slovin on Considerations for Treatment Selection in Nonmetastatic CRPC

August 11th 2021

Susan F. Slovin, MD, PhD, discusses considerations for treatment selection in nonmetastatic castration-resistant prostate cancer.

Rapid Readouts: Results from the Phase 3 VISION Study

August 11th 2021

A. Oliver Sartor, MD, presents data from the American Society of Clinical Oncology 2021 annual meeting from the VISION study of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.

PARP Inhibitors, PSMA-Directed Therapy Augment the Prostate Cancer Armamentarium

August 11th 2021

Antiandrogen agents, PARP inhibitors, and prostate-specific membrane antigen-directed therapy have broadened the armamentarium in prostate cancer.